急性冠状动脉综合征介入术并用替罗非班的近期疗效.pdfVIP

· 418· South China Joumal of Cardiovascular Diseases December 2007 V0l 13，N0 6 · 论 著· 急性冠状动脉综合征介入术并用替罗非班的 近期疗效 陈 坚，李 平，凌 政，姚 光 (广西医科大学第六附属医院心内科，广西玉 林 5370001 摘要： 目的 评价急性冠状动脉综合征病人接受经皮冠状动脉介入术治疗中。使用国产血小板糖蛋白 Ⅱb／IIIa (GPII b／IIIa)受体阻断药替罗非班 (tirofiban)的近期疗效及安全性。方法 急性冠状动脉综 合征行介入治疗病人90例，分成替罗非班组及安慰剂组，替罗非班组剂量 10~g／kg，在3 rain内静脉 注入，然后以每分钟0．1~g／kg维持24—72 h，随访30 d，观察亚急性血栓形成、死亡、心肌梗死和紧 急靶血管血运重建、出血等临床终点事件。结果 两组临床、冠状动脉造影及介入治疗基线特征差异无统 计学意义。替罗非班组及安慰剂组死亡、心肌梗死和紧急靶血管血运重建联合终点事件发生率．分别为2％ 和15％，差异有统计学意义 (P0．05)。两组病人主要、次要及轻微出血事件发生率差异无统计学意义。 结论 替罗非班可改善急性冠状动脉综合征行介入治疗病人的近期疗效，安全性相似。病人耐受性好。 关键词：替罗非班；急性冠状动脉综合征；经皮冠状动脉介入术；联合终点事件 中图分类号：R973．2；R541．4 文献标识码：A 文章编号：1007—9688(2007)06—0418—03 Short-term efficiency of tirofiban in patients with acute coronary syndromes accepted percutaneous coronary intervention CHEN Jian，LI Ping，LING Zheng，YAO Guang (Department of Cardiology， 1]he Sixth Affiliated Hospital of Guangxi Medical University， Yulin Guangxi 537O0o． China) Abstract： Objectives To assess the short．term efficiency and safety of a new platelet GP II b／Ill a antagonist tirofiban in percutaneous coronary intervention(PCI) of acute coronary syndrome(ACS)．Methods ninety patients undergoing PC1 with ACS were assigned into two groups and given tirofiban or placebo respectively． Tirofiban 0．1 mg／kg／min bolus for 3 minutes． followed by 0．1；xg／k9／min for 24~72 h were used． The primary clinical endpoints were the presence of sub—acute thrombosis in PCI of ACS． The composite endpoints wele death， myocardial infraction and revascularization of the target vesse1． The secondary endpoint was hemorrhage events， followed—up thirty days after PCI． Results The baseline clinical and angiographic characteristics and the results of PCI between two groups had no significant difference．The incidence of primary events in tirofibon group wer